Efficacy of Artemisia Pollen Specific Allergen Immunotherapy

Inclusion Criteria:

• presence of seasonal rhinitis symptoms.
• the TNSS was higher than 6 scores in last autumn pollen season.
• artemisia-specific immunoglobulin E (IgE) levels (ImmunoCAP) at least class 3, andhigher than both of ragweed and Humulus IgE levels.
• patients who have been informed of the nature and aims of the study and have giventheir written consent, willing to comply with the protocol.
• patients who are able to understand the information given and the consent and completethe daily record card.

Exclusion Criteria:

• ulcers, inflammation or trauma in the sublingual part;
• oral diseases / oral allergies;
• had surgery within four weeks before screening evaluation;
• Continuous use of systemic glucocorticoids within four weeks before screeningevaluation;
• Any history of severe systemic allergic reaction and eosinophilic esophagitis beforescreening evaluation;
• Suffering from perennial allergic rhinitis;
• Complicated with chronic rhinitis or sinusitis, nasal polyps;
• In the recent pollen season, rhinitis can be relieved without symptomatic treatment;
• Within 2 years before enrollment, diagnosed with a history of moderate and severeasthma or FEV1 less than 70% of the estimated value;
• Applying β Treatment with receptor blockers (including systemic and local drugs) orangiotensin converting enzyme (ACE) inhibitors;
• Participated in clinical trials of other drugs within one month; Receiving otherpollen allergen specific immunotherapy;
• Pregnant and lactating women or those who have pregnancy planning within the pastyear;
• history of immunosuppressive disease (such as HIV infection history), history ofmalignancy, history of autoimmune diseases, history of pulmonary tuberculosis,cardiovascular dysfunction, or other serious diseases of other organ systems judged byresearchers.
• received pollen allergen specific immunotherapy or are receiving allergen specificimmunotherapy within three years.